More about
Evolocumab
News
September 28, 2021
1 min read
Save
Evolocumab gains FDA approval for patients aged 10 years and older with heterozygous FH
Amgen announced that the FDA has approved evolocumab as an adjunct to diet and other LDL-lowering therapies for the treatment of heterozygous familial hypercholesterolemia in pediatric patients aged 10 years and older.